http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+Jun+02/26595235.html si-local-file:///var/storage/secattach/20260603/26595235.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+Jun+02/26595235.html Wed, 03 Jun 2026 07:00:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+Jun+02/26595235.html si-local-file:///var/storage/secattach/20260603/26595235.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+Jun+02/26595235.html Wed, 03 Jun 2026 07:00:00 -0400 O.13483677 VRDN http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html <p>Investing.com -- China's healthcare sector declined 1.3% this week, underperforming the Hang Seng Index which fell 1.7%, as regulators in both the U.S. and China announced plans to increase oversight of licensing agreements.</p><p>The sector is down 8.1% year-to-date, compared to a 1.7% decline in the Hang Seng Index. Contract development and manufacturing organizations and biotechnology companies have outperformed, rising 7.0% and 6.7% respectively.</p><p>The ASCO conference is scheduled to run from Friday through June 2.</p><p>Chinese regulators have tightened rules governing online prescription drug sales, now requiring licensed pharmacist-led reviews of artificial intelligence systems and real-name authentication of buyers.</p><p>Hengrui's HRS-7535, an oral http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html Fri, 29 May 2026 12:07:47 -0400 PFE VRDN http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html <p>Investing.com -- China's healthcare sector declined 1.3% this week, underperforming the Hang Seng Index which fell 1.7%, as regulators in both the U.S. and China announced plans to increase oversight of licensing agreements.</p><p>The sector is down 8.1% year-to-date, compared to a 1.7% decline in the Hang Seng Index. Contract development and manufacturing organizations and biotechnology companies have outperformed, rising 7.0% and 6.7% respectively.</p><p>The ASCO conference is scheduled to run from Friday through June 2.</p><p>Chinese regulators have tightened rules governing online prescription drug sales, now requiring licensed pharmacist-led reviews of artificial intelligence systems and real-name authentication of buyers.</p><p>Hengrui's HRS-7535, an oral http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html Fri, 29 May 2026 12:07:47 -0400 PFE VRDN http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html <p>Investing.com -- China's healthcare sector declined 1.3% this week, underperforming the Hang Seng Index which fell 1.7%, as regulators in both the U.S. and China announced plans to increase oversight of licensing agreements.</p><p>The sector is down 8.1% year-to-date, compared to a 1.7% decline in the Hang Seng Index. Contract development and manufacturing organizations and biotechnology companies have outperformed, rising 7.0% and 6.7% respectively.</p><p>The ASCO conference is scheduled to run from Friday through June 2.</p><p>Chinese regulators have tightened rules governing online prescription drug sales, now requiring licensed pharmacist-led reviews of artificial intelligence systems and real-name authentication of buyers.</p><p>Hengrui's HRS-7535, an oral http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html Fri, 29 May 2026 12:07:47 -0400 PFE VRDN http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html <p>Investing.com -- China's healthcare sector declined 1.3% this week, underperforming the Hang Seng Index which fell 1.7%, as regulators in both the U.S. and China announced plans to increase oversight of licensing agreements.</p><p>The sector is down 8.1% year-to-date, compared to a 1.7% decline in the Hang Seng Index. Contract development and manufacturing organizations and biotechnology companies have outperformed, rising 7.0% and 6.7% respectively.</p><p>The ASCO conference is scheduled to run from Friday through June 2.</p><p>Chinese regulators have tightened rules governing online prescription drug sales, now requiring licensed pharmacist-led reviews of artificial intelligence systems and real-name authentication of buyers.</p><p>Hengrui's HRS-7535, an oral http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html Fri, 29 May 2026 12:07:47 -0400 PFE VRDN http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html <p>Investing.com -- China's healthcare sector declined 1.3% this week, underperforming the Hang Seng Index which fell 1.7%, as regulators in both the U.S. and China announced plans to increase oversight of licensing agreements.</p><p>The sector is down 8.1% year-to-date, compared to a 1.7% decline in the Hang Seng Index. Contract development and manufacturing organizations and biotechnology companies have outperformed, rising 7.0% and 6.7% respectively.</p><p>The ASCO conference is scheduled to run from Friday through June 2.</p><p>Chinese regulators have tightened rules governing online prescription drug sales, now requiring licensed pharmacist-led reviews of artificial intelligence systems and real-name authentication of buyers.</p><p>Hengrui's HRS-7535, an oral http://www.streetinsider.com/General+News/Morgan+Stanley%3A+China+healthcare+sector+dips+1.3%25+amid+licensing+scrutiny/26572745.html Fri, 29 May 2026 12:07:47 -0400 PFE VRDN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+27/26567174.html si-local-file:///var/storage/secattach/20260528/26567174.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+27/26567174.html Thu, 28 May 2026 16:05:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+27/26567174.html si-local-file:///var/storage/secattach/20260528/26567174.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+27/26567174.html Thu, 28 May 2026 16:05:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Press+Releases/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html <p> WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY </li> <li> <b>Goldman Sachs 47th Annual Global Healthcare Conference</b>: Fireside chat on Tuesday, June 9, 2026, at 4:00pm ET in Miami, FL </li> </ul><p> A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian http://www.streetinsider.com/Press+Releases/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html Wed, 27 May 2026 07:00:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Press+Releases/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html <p> WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY </li> <li> <b>Goldman Sachs 47th Annual Global Healthcare Conference</b>: Fireside chat on Tuesday, June 9, 2026, at 4:00pm ET in Miami, FL </li> </ul><p> A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian http://www.streetinsider.com/Press+Releases/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html Wed, 27 May 2026 07:00:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Business+Wire/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html <p> WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY </li> <li> <b>Goldman Sachs 47th Annual Global Healthcare Conference</b>: Fireside chat on Tuesday, June 9, 2026, at 4:00pm ET in Miami, FL </li> </ul><p> A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian http://www.streetinsider.com/Business+Wire/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html Wed, 27 May 2026 07:00:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Business+Wire/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html <p> WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: </p><ul class="bwlistdisc"> <li> <b>Jefferies Global Healthcare Conference</b>: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY </li> <li> <b>Goldman Sachs 47th Annual Global Healthcare Conference</b>: Fireside chat on Tuesday, June 9, 2026, at 4:00pm ET in Miami, FL </li> </ul><p> A live webcast of each presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian http://www.streetinsider.com/Business+Wire/Viridian+Therapeutics+to+Participate+in+Upcoming+June+Investor+Conferences/26553281.html Wed, 27 May 2026 07:00:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+24/26549833.html si-local-file:///var/storage/secattach/20260526/26549833.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+24/26549833.html Tue, 26 May 2026 16:06:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+24/26549833.html si-local-file:///var/storage/secattach/20260526/26549833.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Viridian+Therapeutics%2C++++For%3A+May+24/26549833.html Tue, 26 May 2026 16:06:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Press+Releases/Viridian+Metals+Expands+Drill+Program+to+50+Holes+at+Kraken+Copper-Nickel+Project/26520060.html <p align="justify">OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- <strong>Viridian Metals (CSE: VRDN) </strong>(“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the scope of copper-nickel sulphide mineralization traced over approximately 5 kilometres along the Main Zone. Previous drilling intersected mineralization at roughly 1-kilometre spacing, outlining the scale of the Main Zone discovery. The Company’s 2024 and 2025 drilling campaigns established continuity of mineralization at the sub-kilometre scale within the northern portion of the system through tighter-spaced drilling. The 2026 campaign will connect these http://www.streetinsider.com/Press+Releases/Viridian+Metals+Expands+Drill+Program+to+50+Holes+at+Kraken+Copper-Nickel+Project/26520060.html Tue, 19 May 2026 13:30:00 -0400 VRDN http://www.streetinsider.com/Globe+Newswire/Viridian+Metals+Expands+Drill+Program+to+50+Holes+at+Kraken+Copper-Nickel+Project/26520060.html <p align="justify">OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- <strong>Viridian Metals (CSE: VRDN) </strong>(“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the scope of copper-nickel sulphide mineralization traced over approximately 5 kilometres along the Main Zone. Previous drilling intersected mineralization at roughly 1-kilometre spacing, outlining the scale of the Main Zone discovery. The Company’s 2024 and 2025 drilling campaigns established continuity of mineralization at the sub-kilometre scale within the northern portion of the system through tighter-spaced drilling. The 2026 campaign will connect these http://www.streetinsider.com/Globe+Newswire/Viridian+Metals+Expands+Drill+Program+to+50+Holes+at+Kraken+Copper-Nickel+Project/26520060.html Tue, 19 May 2026 13:30:00 -0400 VRDN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Bellevue+Group+AG/26503909.html si-local-file:///var/storage/secattach/20260515/26503909.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Bellevue+Group+AG/26503909.html Fri, 15 May 2026 14:38:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Bellevue+Group+AG/26503909.html si-local-file:///var/storage/secattach/20260515/26503909.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Bellevue+Group+AG/26503909.html Fri, 15 May 2026 14:38:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Lowered+to+%2426+at+Evercore+ISI/26499331.html Evercore ISI analyst Gavin Clark-Gartner lowered the price target on Viridian Therapeutic (NASDAQ: VRDN) to $26.00 (from $27.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Lowered+to+%2426+at+Evercore+ISI/26499331.html Fri, 15 May 2026 07:15:38 -0400 VRDN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26486746.html si-local-file:///var/storage/secattach/20260513/26486746.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26486746.html Wed, 13 May 2026 16:31:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26486746.html si-local-file:///var/storage/secattach/20260513/26486746.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Viridian+Therapeutics%2C+++++++++++++++++Filed+by%3A+Fairmount+Funds+Management+LLC/26486746.html Wed, 13 May 2026 16:31:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Fairmount+Healthcare+Fund+II+GP+LLC/26486774.html si-local-file:///var/storage/secattach/20260513/26486774.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Fairmount+Healthcare+Fund+II+GP+LLC/26486774.html Wed, 13 May 2026 16:31:00 -0400 O.13483677 VRDN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Fairmount+Healthcare+Fund+II+GP+LLC/26486774.html si-local-file:///var/storage/secattach/20260513/26486774.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Viridian+Therapeutics%2C++++For%3A+May+11++Filed+by%3A+Fairmount+Healthcare+Fund+II+GP+LLC/26486774.html Wed, 13 May 2026 16:31:00 -0400 O.13483677 VRDN http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Lowered+to+%2439+at+Stifel/26483534.html Stifel analyst Alex Thompson lowered the price target on Viridian Therapeutic (NASDAQ: VRDN) to $39.00 (from $48.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Viridian+Therapeutic+%28VRDN%29+PT+Lowered+to+%2439+at+Stifel/26483534.html Wed, 13 May 2026 10:12:57 -0400 VRDN